A systematic review and combined meta‐analysis of concentration of oral amisulpride

摘要

Aims Amisulpride, a first‐line schizophrenia treatment, has shown large interindividual variability in plasma/serum levels, often outside the reference range (100–320 ng/mL). This study aims to clarify the impact of dose, sex, age and related factors for the interpatient variability in amisulpride plasma/serum concentration. Methods Both English and Chinese databases were searched from their inception to May 16, 2019, using the terms: amisulpride and (plasma OR serum OR blood OR “drug monitoring” OR concentration). Studies reporting concentrations and either a dose, associated factor, clinical outcome or side effect were included. Results Fourteen studies with 1628 participants were eventually included. Eligible articles yielded data on drug concentration and dose, averaging 333.9 (95% confidence interval [CI]: 294.5–373.3) ng/mL and 636.2 (95% CI: 549.7–722.6) mg/d, respectively. The calculated mean concentration‐to‐dose (C/D) ratio was 0.60 (95% CI: 0.52–0.67) (ng/mL)/mg. Subgroup analysis suggested that female patients on combined lithium‐amisulpride have higher concentration levels and C/D ratios. Age was slight positive associated with C/D ratio while not for plasma level. Smoker patients have high concentration level than nonsmoking patients but not for C/D. Responsive and nonresponsive groups did not differ in concentration and C/D. Conclusion Pooled concentration levels of amisulpride were higher than recommended with wide individual variation, especially in older patients, female patients and patients taking amisulpride combined with lithium. The specific therapeutic reference range for amisulpride may require reconstruction, which should consider the influence of age, sex, kidney function, drug–drug interactions, different dose regimens and sampling times in future study.